



**AXELGAARD**  
MANUFACTURING CO., LTD.

PRESS RELEASE - UCon; A noninvasive neurostimulation system specifically designed for genital nerve stimulation

Fallbrook, California (September 8, 2022)--Today a new study was announced at the International Continence Society (ICS) 2022 annual meeting in Vienna, Austria. The study will use neuromodulation to treat overactive bladder symptoms like urgency, frequency, and incontinence. In addition, nonobstructive urinary retention and fecal incontinence will also be addressed with neuromodulation.

The study was made possible because a non-invasive neuromodulation device for stimulation (UCon) was built by InnoCon Medical ApS and verification tests were successfully completed. Dedicated dorsal genital nerve (DGN) electrodes have been developed in collaboration with Axelgaard Manufacturing Co., Ltd. using the Company's proprietary Dispense-and-Cure technology. They are heart shaped and are suitable for use in both males and females. The electrodes consist of a silicone shell, a metal connector for the lead and, a customized hydrogel. The hydrogel (developed by Axelgaard Manufacturing Co., Ltd.) ensures optimal tissue friendliness and electrical properties along with biological safety.

This study will enroll a total of 40 patients in 3 different hospitals and was initiated in March 2022. It is expected that the availability of UCon would boost clinical research into DGN stimulation. In addition, UCon would allow DGN stimulation to become a medical treatment because the device has been developed according to requirements for regulatory clearance.



**Intertek**

520 Industrial Way • Fallbrook, CA 92028-2244 • USA  
Tel +1 (760) 451-8000 • Fax +1 (760) 723-2356 • [www.Axelgaard.com](http://www.Axelgaard.com)